Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for...
Dialectic Therapeutics, Inc., a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, announced that the U.S. Food and...
The GRAS Notification Program is a voluntary submission for products intended as food additives. Based on our extensive research, specifications, intended usage, history, preparation,...
The U.S. Food and Drug Administration announced it has made a low-risk determination for the marketing of products, including food, from two genome-edited beef...
The U.S. Food and Drug Administration finalized guidance to help companies prepare to quickly and effectively remove violative products from the market. The guidance...
